← Back to patent-cliff list

Sapitinib

Tier C — Watch / trade

Sapitinib

AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:EGFR, HER2, HER3

Indications (approved):Non-small cell lung cancer, Metastatic breast cancer, Neoplasm, Breast cancer, Oesophageal cancer, Gastric cancer, Colorectal cancer, Solid tumour

Regional status

US
Discontinued
2010-06-01
EU
Phase II
2009-06-01
China
Discontinued
2012-03-31
Japan
Discontinued
2010-06-01

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield 38.1 kg
SAPI-00152805-46-6SAPI-002141699-59-4SAPI-0031196531-33-5SAPI-0041196531-36-8SAPI-0051196531-35-7SAPI-0061196531-37-9SAPI-0071196531-38-0SAPI-0081252041-51-2SAPI-0092106-04-09SAPI-010122-51-0Sapitinib848942-61-0API · Sapitinib
CodeCAS No.Intermediate
SAPI-00152805-46-63-hydroxy-4-methoxybenzonitrile
SAPI-002141699-59-4Availabletert-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate
SAPI-0031196531-33-5tert-butyl 4-(5-cyano-2-methoxyphenoxy)piperidine-1-carboxylate
SAPI-0041196531-36-84-methoxy-3-(piperidin-4-yloxy)benzonitrile hydrochloride
SAPI-0051196531-35-72-(4-(5-cyano-2-methoxyphenoxy)piperidin-1-yl)-N-methylacetamide
SAPI-0061196531-37-92-(4-(5-cyano-2-methoxy-4-nitrophenoxy)piperidin-1-yl)-N-methylacetamide
SAPI-0071196531-38-02-(4-(4-amino-5-cyano-2-methoxyphenoxy)piperidin-1-yl)-N-methylacetamide
SAPI-0081252041-51-2(E)-N,N'-bis(3-chloro-2-fluorophenyl)formimidamide
SAPI-0092106-04-093-chloro-2-fluoroaniline
SAPI-010122-51-0Availabletriethoxymethane
Sapitinib848942-61-02-(4-((4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-N-methylacetamide

Frequently asked questions

What are the approved indications of Sapitinib?

Approved indications include: Non-small cell lung cancer, Metastatic breast cancer, Neoplasm, Breast cancer, Oesophageal cancer, Gastric cancer, Colorectal cancer, Solid tumour.

When does the Sapitinib patent expire?

No public expiry year is available for Sapitinib yet; this page updates once verified.

How many synthesis routes are recorded for Sapitinib?

1 synthesis routes are recorded; the shortest is 7 steps with 38.1 kg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Sapitinib intermediates?

2 intermediate CAS of Sapitinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Sapitinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21